A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Nagai, Hideaki ^a   Ikematsu, Hideyuki ^b   Tenjinbaru, Kazuyoshi ^c   Maeda, Atsushi ^c   Dramé, Mamadou ^d   Roman, François P ^d  

^a TOKYO NATIONAL HOSPITAL   (Japan)

^b Hara Doi Hospital   (Japan)

^c Development and Medical Affairs Division   (Japan)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; INFLUENZA VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CROSS REACTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROTECTION; RHINOPHARYNGITIS; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN INDURATION; SKIN REDNESS; SWEATING; SWELLING; UNSPECIFIED SIDE EFFECT; VIRUS HEMAGGLUTINATION; VIRUS IMMUNITY; ANTIBODY PRODUCTION; ASIAN; BLOOD; CLINICAL TRIAL; CROSS PROTECTION; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS PROTECTION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 78649327318     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-338     Document Type: Article

References (30)

1. H5N1 avian influenza: timeline of major events. Accessed 20 September 2010., http://www.who.int/csr/disease/avian_influenza/2010_03_16_h5n1_avian_influenza_timeline.pdf
2. Avian influenza. Accessed 20 September 2010., http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_06_08/en/index.html
3. Pandemic (H1N1) 2009 - update 105. Accessed 20 September 2010., http://www.who.int/csr/don/2010_06_18/en/index.html
4. Avian Influenza. Accessed 20 September 2010., http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm
5. Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen, Hadisoedarsuno W, Purba W, Santoso H, Septiawati C, Tresnaningsih E, Heriyanto B, Yuwono D, Harun S, Soeroso S, Giriputra S, Blair PJ, Jeremijenko A, Kosasih H, Putnam SD, Samaan G, Silitonga M, Chan KH, Poon LL, Lim W, Klimov A, Lindstrom S, Guan Y, Donis R, Katz J, Cox N, Peiris M, Uyeki TM. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006, 355:2186-2194. 10.1056/NEJMoa060930, 17124016.
6. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, Chunsutthiwat S. Probable Person-to-Person Transmission of Avian Influenza A (H5N1). N Engl J Med 2005, 352:333-340. 10.1056/NEJMoa044021, 15668219.
7. Osterhaus AD. Pre- or post-pandemic influenza vaccine?. Vaccine 2007, 25:4983-4984. 10.1016/j.vaccine.2007.05.033, 17555851.
8. WHO Global Influenza Prepardeness Plan. Accessed 20 September 2010., http://www.who.int/csr/resources/publications/influenza/en/WHO_CDS_CSR_GIP_2005_5.pdf
9. Chu DW-S, Hwang SJ, Lim FS, Oh H, Thongcharoen P, Yang PC, Bock HL, Drame M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435. 10.1016/j.vaccine.2009.07.102, 19683087.
10. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589. 10.1016/S0140-6736(07)61297-5, 17707753.
11. Rumke HC, Bayas JM, de J, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, bad-Santos F, von SF, Drame M, Sanger R, Ballou WR. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-2388. 10.1016/j.vaccine.2008.02.068, 18407382.
12. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3:e1665. 10.1371/journal.pone.0001665, 2253495, 18301743.
13. Schwarz T, Horacek T, Knuf M, Damman H, Roman F, Dramé M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290. 10.1016/j.vaccine.2009.01.040, 19856521.
14. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368:991-997. 10.1016/S0140-6736(06)69294-5, 16980114.
15. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van AG, Wettendorff MA, Hanon E, Osterhaus AD. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3:e1401. 10.1371/journal.pone.0001401, 2151135, 18167560.
16. Availability of new H5N1 prototype strain for influenza pandemic vaccine development. Accessed 20 September 2010., http://www.who.int/csr/disease/avian_influenza/guidelines/avianinfluenzastrains2006/en/index.html
17. Masuda M, Sugita S, Kuroda K, Nishimura H. H5N1 influenza vaccination policy in Japan. Lancet Infect Dis 2009, 9:266-267. 10.1016/S1473-3099(09)70106-9, 19393952.
18. Tada Y. Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2008, 2:261-266. 10.1111/j.1750-2659.2008.00066.x, 19453403.
19. Note for guidance on harmonisation of requirements for influenza vaccines. Accessed 20 September 2010., http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf
20. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays. J Clin Microbiol 1999, 37:937-943. 88628, 10074505.
21. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103:163-171. 10.1016/j.virusres.2004.02.029, 15163505.
22. Reed LJ, Muench H. A simple method for estimating 50% endpoints. The American Journal of Hygiene 1938, 27:493-497.
23. Summary of Product Characteristics. , http://ec.europa.eu/health/documents/community-register/2008/2008051443509/anx_43509_en.pdf
24. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008, 14:121-128. 10.3201/eid1401.061283, 2600140, 18258091.
25. Yong-Hwa Lee L, Ha DLA, Simmons C, de Jong MD, Chau NVV, Schumacher R, Chun Peng Y, McMichael AJ, Farrar JJ, Smith GL, Townsend ARM, Askonas BA, Rowland-Jones S, Dong T. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008, 118:3478-3490. 2542885, 18802496.
26. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008, 180:1758-1768.
27. Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673. Epub 2010 Apr 12, 10.1172/JCI41902, 2860935, 20389023.
28. WHO Global Alert and Response (GAR), March 2009. Accessed 20 September 2010., http://www.who.int/csr/disease/avian_influenza/guidelines/nomenclature/en/index.html
29. Neumann G, Green MA, Machen CA. Evolution of highly pathogenic H5N1 avian influenza viruses and the emergence of dominant variants. J Gen Virol 2010, 91:1984-1995. 10.1099/vir.0.020750-0, 20392897.
30. WHO Global Alert and Response (GAR), Sept 2008. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use in human vaccines Accessed 20 September 2010., http://www.who.int/csr/disease/avian_influenza/guidelines/h5n1virus/en/index.html